In the SFMCs of RA patients, the Exo-srIκB treatment showed a trend of decreasing the frequency of IL-17A-producing cells, and it significantly lowered the frequency of GM-CSF-producing cells compared to the Exo-Naïve treatment (Fig. 3 B).
← all excerpts
Exosome-mediated delivery of super-repressor IκBα alleviates inflammation and joint damages in rheumatoid arthritis.
1
—
—